The authors mapped a wide range of cannabis-derived food products, from nutritionally oriented hemp seed foods to pharmacologically active THC edibles, CBD-containing items, cannabis-infused beverages, and emerging cannabinoids such as delta-8-THC and HHC.

This breadth matters clinically because these categories are not interchangeable. A hemp protein powder and a THC-dosed gummy sit in the same broad market but carry very different exposure risks.

The review highlights that oral delta-9-THC has a distinct pharmacokinetic profile compared with inhaled cannabis, including delayed onset, prolonged effects, and first-pass hepatic metabolism that produces the active metabolite 11-hydroxy-THC.

That profile, combined with high interindividual variability, helps explain why edible dosing is harder to predict than smoked or vaporized cannabis, and why repeated dosing before an initial dose takes effect is a recognized risk.

The authors connect delayed and variable onset to real-world harms: repeated dosing, unexpected intoxication, accidental pediatric exposure, and emergency department presentations.

CBD products carry a separate set of concerns around dose accuracy, purity, hepatic effects, and drug interactions, while delta-8-THC, HHC, and related emerging cannabinoids have limited toxicological data and inconsistent regulation across markets.

The review calls for harmonized product definitions, validated analytical testing methods, reliable labeling, child-resistant packaging, systematic adverse-event surveillance, and dose-based regulation.

None of these exist uniformly today, which is part of why the same cannabinoid category can be tightly regulated in one market and sold with minimal oversight in another.

For patients using cannabis or hemp-derived food products, the practical questions are about product category, labeled versus actual cannabinoid content, dosing form, and storage where children or pets could access the product.

This review supports asking those questions explicitly rather than assuming that an edible product carries the same risk profile as inhaled cannabis or that hemp-derived items are automatically safer than dispensary products.

Edible and hemp-derived cannabinoid products have expanded far faster than the regulatory frameworks meant to govern them, creating a market where nutritionally framed hemp foods, pharmacologically dosed THC edibles, and largely unregulated emerging cannabinoids sit side by side on the same shelf.

The practical response is not to treat all of these products as equally risky or equally safe, but to keep asking what is actually in a given product, how it was tested, and how predictably it behaves once it is eaten rather than inhaled.

I read this review as a useful organizing document rather than a dramatic new finding. The pharmacokinetic point about delayed, variable onset is one I discuss with patients often, because it is the single biggest reason edible dosing goes wrong.

The part I would keep closest to clinical practice is the gap around delta-8-THC, HHC, and similar emerging cannabinoids. Patients often assume a hemp-derived label means a gentler or better-tested product, and this review is a reminder that the opposite can be true.

A Four-Step Reading Frame